Open the map

AmgenAMGN

Biotech & innovation · NASDAQ · USA

$407.44
Down 1.4% todayClose

Up 23.0% this year and +13.7% since June 26, ahead of the life science sector at +10.7%. Amgen supplies 1 mapped company and buys from 4.

Market cap
$223B
This year
+23.0%
1 year
+36.9%
P/E
25.5
P/S
5.9
P/B
19.1

Price vs the life science sector

since Jun 26AMGNLife science sector, equal weight
Amgen (AMGN) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. AMGN: +13.7% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.0%+10%+20%Jun 26AugSepOct 8AMGN +13.7%Sector +10.7% Amgen (AMGN) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. AMGN: +13.7% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.0%+10%+20%Jun 26AugSepOct 8AMGN+13.7%Sector+10.7%

Supply chain

4 suppliers · 1 customer
SUPPLIERS →→ CUSTOMERSDanaher (DHR)DHRDanaher−0.5%West Pharmaceutical Services (WST)WSTWest Pharmaceutical…−0.9%IQVIA Holdings (IQV)IQVIQVIA Holdings+0.3%Thermo Fisher Scientific (TMO)TMOThermo Fisher Scien…−1.5%Cencora (COR)CORCencora+1.3%AMGNAmgen

Suppliers 4

Customers 1

Open the full chain →

About Amgen

Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.

Theme exposure

BiotechOncologyObesity exposureObesity

Products

  • Oncology & haematology
  • Immunology
  • Obesity pipeline (MariTide)

Competitors

Risks

  • Patent expirations
  • Clinical risk in pipeline

Same segment: Biotech & innovation

Innovation-driven biotech companies focused on novel treatment modalities. Segment 3 of 8 in the Medicine, pharma & life science value chain.

Gilead SciencesGILD+0.2%Vertex PharmaceuticalsVRTX−0.5%ModernaMRNA+0.3%RegeneronREGN−0.3%BiogenBIIB−1.7%Alnylam PharmaceuticalsALNY+0.1%United TherapeuticsUTHR−2.2%IncyteINCY−0.6%

Compare AMGN

Side by side with the largest companies in the same segment.

AMGN vs GILDAMGN vs VRTXAMGN vs MRNAAMGN vs REGNAMGN vs BIIBAMGN vs ALNY

See where Amgen sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.

Open the Life science value chain →